Cartesian Therapeutics, Inc. Common Stock (RNAC) Stock
NASDAQ · RNAC
7.12
Fundamentals
Market cap
$224.19M
Price / Earnings ratio
-1.5x
Price / Sales ratio
156.1x
Price / Book ratio
-1.8x
Return on assets
-46.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
New Strong Sell Stocks for July 1st
NeutralRNACJuly 1, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 1st
RNAC

24/7 Wall Street
Substantial Insider Buying: American Express, Asana, and More
NeutralRNACMarch 30, 2025
24/7 Wall StreetNeutral
Substantial Insider Buying: American Express, Asana, and More
RNAC

24/7 Wall Street
Insider Buying Slows, but Not for 7 These Buyers
NeutralRNACOctober 13, 2024
24/7 Wall StreetNeutral
Insider Buying Slows, but Not for 7 These Buyers
RNAC
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 3 articles
published over the past 14 days
Latest news

Zacks Investment Research
New Strong Sell Stocks for July 1st
NeutralRNACJuly 1, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 1st
RNAC

24/7 Wall Street
Substantial Insider Buying: American Express, Asana, and More
NeutralRNACMarch 30, 2025
24/7 Wall StreetNeutral
Substantial Insider Buying: American Express, Asana, and More
RNAC

24/7 Wall Street
Insider Buying Slows, but Not for 7 These Buyers
NeutralRNACOctober 13, 2024
24/7 Wall StreetNeutral
Insider Buying Slows, but Not for 7 These Buyers
RNAC
About Cartesian Therapeutics, Inc. Common Stock
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
SectorHealthcare
IndustryBiotechnology
Employees75
CEODr. Carsten Brunn Ph.D.
IPO DateJun 21, 2016
HeadquartersFrederick, MD
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Carsten Brunn Ph.D. | President, CEO & Chairman of the Board | 1971 |
| Mr. Blaine T. Davis | Chief Financial Officer | 1974 |
| Dr. Emily English Ph.D. | Chief Operating Officer | 1980 |
| Ms. June Seymour | Chief Accounting Officer | 1978 |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | — |
| Dr. Peter G. Traber M.D. | Head of R&D | 1955 |
Fundamentals
Valuation
Market cap$224.19M
Price-to-sales ratio156.06
Price-to-book value-1.84
Price-earnings ratio-1.50
Return on Equity198.00%
Return on Sales-9069.00%
Return on Assets-46.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-5.94
Income Statement
Average volume113,476
EBITDA$-157.72M
1 year high (52w)$11.00
1 year low (52w)$5.60
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$38.00
Est return
412.13%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.4 | -23.4 | +17.9 | -20.3 |



